IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, Italy.
Eur J Nucl Med Mol Imaging. 2022 May;49(6):1939-1950. doi: 10.1007/s00259-021-05666-9. Epub 2022 Jan 5.
Hyposmia is a common feature of COVID-19 and Parkinson's disease (PD). As parkinsonism has been reported after COVID-19, a link has been hypothesized between SARS-CoV2 infection and PD. We aimed to evaluate brain metabolic correlates of isolated persistent hyposmia after mild-to-moderate COVID-19 and to compare them with metabolic signature of hyposmia in drug-naïve PD patients.
Forty-four patients who experienced hyposmia after SARS-COV2 infection underwent brain [F]-FDG PET in the first 6 months after recovery. Olfaction was assessed by means of the 16-item "Sniffin' Sticks" test and patients were classified as with or without persistent hyposmia (COVID-hyposmia and COVID-no-hyposmia respectively). Brain [F]-FDG PET of post-COVID subgroups were compared in SPM12. COVID-hyposmia patients were also compared with eighty-two drug-naïve PD patients with hyposmia. Multiple regression analysis was used to identify correlations between olfactory test scores and brain metabolism in patients' subgroups.
COVID-hyposmia patients (n = 21) exhibited significant hypometabolism in the bilateral gyrus rectus and orbitofrontal cortex with respect to COVID-non-hyposmia (n = 23) (p < 0.002) and in middle and superior temporal gyri, medial/middle frontal gyri, and right insula with respect to PD-hyposmia (p < 0.012). With respect to COVID-hyposmia, PD-hyposmia patients showed hypometabolism in inferior/middle occipital gyri and cuneus bilaterally. Olfactory test scores were directly correlated with metabolism in bilateral rectus and medial frontal gyri and in the right middle temporal and anterior cingulate gyri in COVID-hyposmia patients (p < 0.006) and with bilateral cuneus/precuneus and left lateral occipital cortex in PD-hyposmia patients (p < 0.004).
Metabolic signature of persistent hyposmia after COVID-19 encompasses cortical regions involved in olfactory perception and does not overlap metabolic correlates of hyposmia in PD.
嗅觉减退是 COVID-19 和帕金森病(PD)的常见特征。由于 COVID-19 后已报道出现帕金森病,因此假设 SARS-CoV2 感染与 PD 之间存在关联。我们旨在评估轻度至中度 COVID-19 后孤立性持续性嗅觉减退的脑代谢相关性,并将其与未经药物治疗的 PD 患者嗅觉减退的代谢特征进行比较。
44 名 SARS-COV2 感染后出现嗅觉减退的患者在康复后 6 个月内接受脑 [F]-FDG PET 检查。嗅觉通过 16 项“Sniffin' Sticks”测试进行评估,患者分为持续性嗅觉减退(COVID-嗅觉减退和 COVID-无嗅觉减退)。在 SPM12 中比较了 COVID 亚组的脑 [F]-FDG PET。COVID-嗅觉减退患者也与 82 名未经药物治疗的嗅觉减退 PD 患者进行了比较。多元回归分析用于识别患者亚组中嗅觉测试评分与大脑代谢之间的相关性。
与 COVID-无嗅觉减退患者(n=23)相比,COVID-嗅觉减退患者(n=21)双侧直回和眶额皮质的代谢明显降低(p<0.002),中颞和上颞回、内侧/中额回和右侧岛叶的代谢也降低(p<0.012)。与 COVID-嗅觉减退相比,PD-嗅觉减退患者双侧下/中枕叶和楔前叶代谢降低。在 COVID-嗅觉减退患者中,嗅觉测试评分与双侧直回和内侧额回以及右侧中颞和前扣带回的代谢直接相关(p<0.006),与 PD-嗅觉减退患者双侧楔前叶/楔叶和左侧外侧枕叶皮质的代谢直接相关(p<0.004)。
COVID-19 后持续性嗅觉减退的代谢特征包括参与嗅觉感知的皮质区域,与 PD 中嗅觉减退的代谢相关性不重叠。